Last updated on March 2020

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss


Brief description of study

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.

Detailed Study Description

The purpose of this Phase 1, multicenter, open-label study is to determine the maximum tolerated dose (MTD) of AG-270, administered as a single agent or in combination with taxane-based chemotherapy, and to characterize its dose-limiting toxicities (DLTs) when given daily by mouth to participants with advanced solid tumors or lymphoma with homozygous deletion of methylthioadenosine phosphorylase (MTAP).

In each arm of the study, successive cohorts of participants will receive increasing oral doses of AG-270 to determine the MTD, the dose with maximum pharmacologic activity or the maximum feasible dose, as a single agent and in combination with taxane-based chemotherapy. In the subsequent dose-expansion parts of the study, additional participants in each treatment arm will be treated at the MTD (or one of the described alternative doses) to further characterize that dose's safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and to detect preliminary evidence of anti-tumor activity.

Clinical Study Identifier: NCT03435250

Find a site near you

Start Over

New Haven

New Haven, CT United States
  Connect »

Boston

Boston, MA United States
  Connect »

New York

New York, NY United States
  Connect »

Nashville

Nashville, TN United States
  Connect »

Villejuif Cedex

Villejuif Cedex, France
  Connect »

Barcelona

Barcelona, Spain
  Connect »